rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Tada Masahiro
Mito Takanori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients had to fulfill all of the following criteria to be included in the study: aged >=65 years at the time of RA diagnosis between 1 January 2015 and 31 December 2023 (ICD-10 codes M05, M060, M062, M063, M068, M069, excluding RS3PE syndrome [standard injury code: 8844120], wrist deformity [standard injury code: 8845190], and ulnar deviation [standard injury code: 8845158]); with at least one prescription for a DMARD or oral glucocorticoid within 1 year of the first RA diagnosis; and with a record of data in the DeSC database for at least 180 days prior to the index date.
Exclusion criteria
Exclusion criteria: No exclusion criteria were set for the primary study endpoint. For secondary endpoints, individuals who lacked prescription records for DMARDs or oral corticosteroids within 1 year of the index date were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint was the prevalence of dementia by year (2015-2023) in all patients with RA aged >=65 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints were: annual incidence of dementia in patients with RA aged 65-74 and >=75 years, status of DMARD prescriptions in patients with RA aged 65-74 and >=75 years who developed dementia, and survival time analysis for new prescriptions or increased doses of oral glucocorticoids in patients aged 65-74 and >=75 years who developed dementia. | — |
Contacts
Public ContactKeita Fujimoto
Eisai Co., Ltd.,
Outcome results
None listed